Simplexia
Simplexia develops a vaccine against genital herpes and is one out of four biomedical companies and projects to be granted by GöteborgBIO and Sahlgrenska Science Park in 2010.
(Project funded for 2010)

Arterion AB is a Göteborg-based company that develops artificial blood vessels made from bacterial cellulose. These artificial blood vessels may ultimately be able to replace narrow blood vessels, which cannot be replaced using today´s technology.
(Project funded for 2010)

Anna-Carin Olin leads a joint project for the diagnosis of respiratory ailments. The project, Diagnos 10 andetag (Diagnosis 10 Breaths), is a unique non-invasive method for the collection and analysis of particles in the patient´s expelled air for the purpose of diagnosis of respiratory ailments. The most immediate goal of the project is to demonstrate the method´s commercial potential and clinical benefit in specific applications.
(Project funded for 2010)

MIVAC Development AB is a pharmaceutical company that focuses on research, development and commercialisation of innovative treatments for autoimmune ailments, allergy therapies, treatments for Alzheimer´s disease and vaccines. Within a project entitled “Immunotherapy and the diagnosis of Alzheimer´s disease" the company has developed a specific antibody against toxic components that cause Alzheimer´s disease. The verification grant will be used to verify the antibody´s active mechanism and to show proof of concept through a variety of studies. The end goal is to develop this antibody into both a drug and a diagnostic tool.
(Project funded for 2010) 

Promimic AB
The company develops and markets a unique implant surface which has shown to dramatically accelerate osseointegration.  The modification can be applied onto various types of substrates, including metals, ceramics and polymers. As a conclusion, the innovation can convert any implant surface, regardless of its dimensions and structure, to a surface that to great extent resembles that of natural human bone tissue.
(Project funding for 2009)

Observe Medical AB
The company works with the development of a new digital technology aiming to facilitate the surveillance of kidney function on patients during operation or intensive care.
(Project funding for 2009)

Encubator AB /Allergy Vaccine Project
A new idea stemming from Sahlgrenska Academy makes it possible to create allergy-free generations through educating the immune system. A natural and user-friendly vaccine for children that will give a broad and life-long protection against allergy development is currently being developed by one of the projects in the incubator of Encubator.
The project has patent protected a specific bacterium with the ability to stimulate the immune system in order to avoid allergy development. The effect of the bacterium was first found in children who did not develop allergy and the mechanism has been proven in mice studies.
(Project funding for 2009)

Fungea AB
The company develops diagnostic tools for fungal infections with focus on invasive candida infection.
(Project funding for 2009)

NemerPharma
Production of a marine bioactive compound for pharmaceutical applications.
(Project funding for 2009)

Immune blockade of autoimmune diseases
Academic research project
(Project funding for 2008)

Syspiro Diagnostics
The company is developing a new type of monitoring device that is intended to provide obstetricians with reliable and continuous information about the foetus´s health during birth. The aim is to reduce the risk of a lack of oxygen supply to the foetus and thus also reduce the number of unnecessary emergency Caesarean sections.

Ortoma
Ortoma offers a complete system — from diagnosis to completed surgery — for patients suffering from spinal disc degeneration. We provide customized disc replacement through delicate surgery — a perfect alternative to fixation.
(Project funding for 2008)

Interdisciplinary cooperation to solve absorption problems with promising substances in oncology
Academic research project
(Project funding for 2008)

First Aid for aneurysmal disease
Academic research project
(Project funding for 2008)

Verification for a Microwave Hyperthermia System
Academic research project
(Project funding for 2008)

Treatment of advanced renal cancer with NC001
Academic research project
(Project funding for 2008)

PORENIX
Innovative nanotechnology for advanced filtering and bioseparation
(Project funding for 2008)

Anti-Resistin - New Treatment for Endemic Diseases
Three common yet so very different diseases such as diabetes, rheumatoid arthritis and arteriosclerosis, have proved to share the same underlying inflammatory mechanisms. By inhibiting a specific protein - resistin - a future treatment for these endemic diseases can be found.
(Project funding for 2005, 2006, 2007)

Arterion (Tissue Engineered Blood Vessels, TEBV)
The project aims to commercially develop cellulose based blood vessels which is a unique and very cost effective way to do it. The project is based on research conducted at Chalmers University of Technology and Göteborg University. Formerly a GIBBS project.
(Project funding for 2007)

Image Analyses Allowing More Time for Other Things - BioPix
BioPix offers an easy-to-use computer programme for image analysis for biomedical research teams and pharmaceutical companies. It makes it easy to automatically quantify large quantities of images and biological preparations at a quality suitable for both publication in scientific journals and effective studies in pharmaceutical companies, as well for use in pathology where large quantities of samples are analysed every day. BioPix makes everyday work easier for many different users.
(Project funding for 2006 and 2007)

CIVO BioScreening - optimises a new generation of biomaterials
A spin-out from Göteborg University and Chalmers University of Technology, which has developed a service concept to screen large numbers of polymers for their suitability in controlled-release drug implants and biomaterials. The technique could replace the existing trial-and-error approach and support biomaterials companies to predict how active substances are eluting from different biomaterials.  
(Project funding for 2006)

DuoCort   
Development of a new cortison formula to be used mainly against chronic adrenal insufficiency.
(Project funding for 2006)

"Little Y"
New project to CVM. Not much can be said at this point in time due to a pending patent process.
(Project funding for 2007)

Midorion - Improved understanding of human diseases
Technology project focusing on the development of a new generation of tools measuring extremely low concentrations of substances/molecules. Midorion utilizes a unique patented method for ultra-sensitive biosensors. The innovation originates from interdisciplinary academic research within miniaturization and nanoscale fabrication, along with advanced chemistry coupling at Chalmers University of Technology and Göteborg University.
(Project funding for 2006)

ScreenHelp to Boost Public Research Initiatives
Before a pharmaceutical candidate can be considered for clinical trials, a screening process is needed to determine which compounds give the intended effect. Screening is expensive, which means that new research ideas from universities and small biotech companies run the risk of not being taken up. This is the background to GöteborgBIO´s ScreenHelp initiative from 2005 and MedCoast Scandinavia´s major platform project Chemical Biology that began in autumn 2005, both designed to create the prerequisites to strengthen the region as a successful biotech cluster.
(Project funding for 2005 and 2006)

Sportheart
The project aims to reduce mortality rate among teenagers performing sports through web based collection of and validation of relevant data.
(Project funding for 2007)

Cardiac Progenitor Cells for Treatment of Heart Disease
Ischemic heart disease is responsible for 50 percent of the mortality of the population of the western world. One serious condition is myocardial infarction. Even in cases where the patient is successfully treated, it leads, to a varying extent, to the formation of scar tissue in the heart. The result is coronary insufficiency with a prognosis no better than for severe forms of cancer. We are now collaborating to find new treatments using heart stem cells.
(Project funding for 2005, 2006, 2007)

New Technology for Reseach on Stem Cells and Obesity
TATAA Biocenter is a world-leader in real time PCR, a technology that has many different fields of application. Among other things it can be used to quickly and with high sensitivity measure the expression of specific genes that are affected in different illnesses or that are potential targets for new pharmaceuticals. The same technology is being used in two research projects, in the fields of stem cells and obesity respectively.
(Funding for 2006)